Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod

Clinical and Experimental Dermatology

Volumn 33, Issue 1, 2008, Pages 74-76

  Mashiah, J ^a   Brenner, S ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; CELL ANTIGEN; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; LISTERIA MONOCYTOGENES VACCINE; MEMBRANE ANTIGEN; RECOMBINANT VACCINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY BLOOD LEVEL; BASAL CELL CARCINOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; CYTOKINE PRODUCTION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; INNATE IMMUNITY; MELANOCYTE; MOLLUSCUM CONTAGIOSUM; OXIDATIVE STRESS; PAGET SKIN DISEASE; PATHOGENESIS; PIGMENT CELL; PRIORITY JOURNAL; SERUM; SHORT SURVEY; TH1 CELL; UNITED STATES; VITILIGO;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; HUMANS; VITILIGO;

EID: 37349048260     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2007.02520.x     Document Type: Short Survey

References (13)

1. Brown T, Zirvi M, Cotsarelis G, Gelfand JM. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol 2005 52 : 715 16.
2. Freedberg IM, Eisen AZ, Wolf K et al. Fitzpatrick's Dermatology in General Medicine, 6th edn. New York : McGraw-Hill, 2003.
3. Nagai H, Hara I, Horikawa T et al. Elimination of CD4 (+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J Invest Dermatol 2000 115 : 1059 64.
4. Seckin D, Durusoy C, Sahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol 2004 21 : 577 9.
5. YuHS, Chang KL, YuCL et al. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997 108 : 527 9.
6. Jimbow K, Chen H, Park JS, Thomas PD. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol 2001 144 : 55 65.
7. Dahl MV. Imiquimod: a cytokine inducer. J Am Acad Dermatol 2002 47 (4 (Suppl. s205 8.
8. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002 27 : 571 7.
9. Miller RL, Tomai MA, Harrison CJ, Bernstein DI. Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int Immunopharmacol 2002 2 : 443 51.
10. Barnetson RS, Satchell A, Zhuang L et al. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol 2004 29 : 639 43.
11. Craft N, Bruhn KW, Nguyen BD et al. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 2005 175 : 1983 90.
12. Michalopoulos P, Yawalkar N, Bronnimann M et al. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol 2004 151 : 903 6.
13. Phan GQ, Attia P, Steinberg SM et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001 19 : 3477 82.